Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan

Hoshi, Shu-ling; Kondo, Masahide; Okubo, Ichiro

doi:10.1371/journal.pone.0139140

Cited by 34 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Japan, both PPSV23 and PCV13 have been used in the elderly to prevent pneumococcal infections since the approval of extended use of PCV13 in June 2014. The national immunization program launched in October 2014 for those aged ≥65 years only subsidized PPSV23 [17]. Widespread adoption of ACIP recommendations would potentially improve the efficacy of pneumococcal immunization.…”

Section: Discussionmentioning

confidence: 99%

Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review

et al. 2017

View full text Add to dashboard Cite

BackgroundAmong the different serotypes of Streptococcus pneumoniae, serotype 3 has received global attention. We report the fatal case of a 76-year-old Japanese man who had an invasive pneumococcal disease associated with pneumonia caused by serotype 3 S. pneumoniae.Case presentationThe patient had a history of hypertension, laryngeal cancer, chronic obstructive pulmonary disease, and type 2 diabetes mellitus. Following a cerebral arteriovenous malformation hemorrhage, he underwent surgery to remove the hematoma and began rehabilitation. On day 66 of hospitalization, he suddenly developed a fever, and coarse crackles and wheezes were heard in his right lung. A diagnosis of hospital-acquired aspiration pneumonia was made, and initial treatment with piperacillin/tazobactam was started. Teicoplanin was added after S. pneumoniae was isolated from the blood culture, however, the patient died 5 days later. The S. pneumoniae detected in the sputum smear was serotype 3, showed mucoid colonies and susceptibility to penicillins, cephalosporins, carbapenems, and levofloxacin, but resistance to erythromycin.ConclusionWe experienced a fatal case of pneumonia caused by mucoid serotype 3 S. pneumoniae with a thick capsule. Serotype 3-associated pneumonia may develop a wider pulmonary infiltrative shadow, a prolonged therapeutic or hospitalization course, and a poor outcome. Careful observation and intervention are required, and the use of additional antibiotics or intravenous immunoglobulins should be considered in such cases. Pneumococcal immunization is also an important public health measure to minimize the development of severe infections caused by serotype 3 strains.

show abstract

Section: Discussionmentioning

confidence: 99%

Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Sobre o local de realização dos estudos analisados, treze deles foram conduzidos em países europeus [15,20,[120][121][122][123][124][125][126][127][128][129][130]; nove, nos Estados Unidos [131][132][133][134][135][136][137][138][139]; três, na América Latina (dois no Brasil [46,140] e um na Colômbia [141]); um foi conduzido no Japão [142]; e um na Turquia [143]. A Erro!…”

Section: Estudos Incluídosunclassified

“…Todos os estudos usaram como base modelos estáticos. O modelo de Markov foi utilizado por 12 estudos [20,46,120,125,126,131,132,[134][135][136][137]142]; seis estudos utilizaram árvore de decisão [122,123,138,140,141,143]; seis descreveram-se como estudos de coorte sem explicitar o tipo de modelo utilizado [15,121,124,127,128,130]; e três não citaram qual modelo foi utilizado [129,133,139].…”

Section: Características Metodológicas Dos Estudos Incluídosunclassified

“…Quanto ao horizonte temporal, 44,4% (12 de 27 estudos) assumiram que o modelo acompanha a coorte por toda a vida [20, 121, 124-126, 128, 131, 134-137, 139] e 33,3% (nove estudos) utilizaram cinco ou seis anos de horizonte temporal [15,120,123,129,130,138,140,141,143]. Apenas três estudos utilizaram um horizonte temporal de 10 a 15 anos [46,127,142] e três estudos mais antigos não declararam claramente o horizonte temporal utilizado [122,132,133].…”

Section: Características Metodológicas Dos Estudos Incluídosunclassified

“…A Tabela resume as informações sobre estratégias, cobertura e eficácias vacinais adotadas. Com exceção do estudo de Hoshi e colaboradores [142], todos os demais realizaram uma comparação com a estratégia "não vacinar". O estudo de Hoshi realizou a comparação do atual calendário de vacinação em idosos no Japão (onde o paciente recebe apenas uma dose da VPP23) com um cenário em que a população passa a receber apenas a VPC13 ou diferentes esquemas de revacinação com a própria VPP23 [142].…”

Section: Estratégias Cobertura E Eficácias Vacinaisunclassified

See 2 more Smart Citations

Revisão sistemática de estudos de avaliação econômica da vacinação universal em adultos acima de 60 anos de idade com a vacina pneumocócica polissacarídea 23-valente

Nishikawa¹

View full text Add to dashboard Cite

Revisão sistemática de estudos de avaliação econômica da vacinação universal em adultos acima de 60 anos de idade com a vacina pneumocócica polissacarídea 23-valente Dissertação apresentada à Faculdade de Medicina da Universidade de São Paulo para obtenção do título de Mestre em Ciências Programa de Medicina Preventiva Orientadora: Profa. Dra. Patrícia Coelho de Soárez São Paulo 2018 Dedico esta dissertação aos meus avós, Seiichi Nishikawa, Sumi Nishikawa, Akira Matsumoto e Kimiko Matsumoto, que saíram de sua terra natal e batalharam muito para que seus netos tivessem sucesso, honra e orgulho de suas escolhas. A minha mãe, Kayoko Matsumoto, por sempre exigir o meu melhor e pela ajuda incondicional. A minha mestra Tamie Kitahara, pelos ensinamentos de vida e pela dedicação que sempre teve comigo. Ao mestre Tadashi Komesu, que com muita energia positiva sempre me ensinou que devemos seguir em frente, na alegria e na tristeza. Agradecimentos Durante o período do mestrado, foram muitas as alegrias e tristezas, assim como acontece em toda nossa existência. Nesta caminhada, sempre contei com o apoio de diversas pessoas, que doaram o que tinham de si para tornar mais esse passo possível. Meus sinceros votos de agradecimento à professora Dra. Patrícia Coelho de Soárez, minha orientadora, por todo o profissionalismo, paciência e compreensão ao longo deste percurso. Agradeço com toda sinceridade, pelo seu tempo e entusiasmo, mesmo em momentos difíceis, e por sempre me aguardar com um sorriso em cada etapa do projeto. À professora Dra. Ana Marli Christovan Sartori, pelo apoio incondicional e ensinamentos. À Giulia Marcelino Mainardi, pelo importante trabalho e parceria como segunda revisora do presente estudo. Aos alunos do grupo, Tania Yuba, Juliana Kodaira Viscondi e Roseli Fernandes, pela companhia e momentos de descontração, que possibilitaram a jornada ser mais leve e divertida. ABSTRACT Nishikawa AM. Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older [dissertation]. São Paulo: "Faculdade de Medicina, Universidade de São Paulo"; 2018. INTRODUCTION: Infections caused by Streptococcus pneumoniae are one of the main causes of morbidity and mortality in the world, particularly in developing countries, generating a significant clinical and economic impact. Children under 2 years old, adults ³60 years old and populations with cronic conditions are the most affected populations.Due to the increase in antibiotic resistance and the increase of the disease's consequences, primary prevention of the disease is being discussed with antipneumococcal vaccination as one of the most effective public health strategies in reducing the burden of the disease. OBJECTIVE: To systematically review and evaluate the quality of the reported economic evaluation studies of the 23-valent pneumococcal polysaccharide vaccine in the elderly immunization with the aim to compare the different methodological strategies adopted by the published studies and discuss ...

show abstract

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions

Rozenbaum,

Chilson,

Farkouh

et al. 2024

Infect Dis Ther

View full text Add to dashboard Cite

Introduction A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years with immunocompromising conditions (IC) versus one and two doses of 23-valent pneumococcal polysaccharide vaccine (PPSV23), respectively. Methods A probabilistic model was employed to depict 10-year risk of clinical outcomes and economic costs of pneumococcal disease, reduction in life years from premature death, and expected impact of vaccination among one cohort of children with CMC+ and IC aged 6 years. Vaccine uptake was assumed to be 20% for both PCV20 and PPSV23. Cost per quality-adjusted life year (QALY) gained was evaluated from the US societal and healthcare system perspectives; deterministic and probabilistic sensitivity analyses (DSA/PSA) were also conducted. Results Among the 226,817 children with CMC+ aged 6 years in the US, use of PCV20 (in lieu of PPSV23) was projected to reduce the number cases of pneumococcal disease by 5203 cases, medical costs by US$8.7 million, and nonmedical costs by US$6.2 million. PCV20 was the dominant strategy versus PPSV23 from both the healthcare and societal perspectives. In the PSA, 99.9% of the 1000 simulations yielded a finding of dominance for PCV20. Findings in analyses of children with IC aged 6 years in the USA were comparable (i.e., PCV20 was the dominant vaccination strategy). Scenario analyses showed that increasing PCV20 uptake to 100% could potentially prevent > 22,000 additional cases of pneumococcal disease and further reduce medical and nonmedical costs by US$70.0 million among children with CMC+ and IC. Conclusions Use of PCV20 among young children with CMC+ and IC in the USA would reduce the clinical burden of pneumococcal disease and yield overall cost savings from both the US healthcare system and societal perspectives. Higher PCV20 uptake could further reduce the number of pneumococcal disease cases in this population. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-024-00944-z.

show abstract

Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan

Cited by 34 publications

References 24 publications

Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review

Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review

Revisão sistemática de estudos de avaliação econômica da vacinação universal em adultos acima de 60 anos de idade com a vacina pneumocócica polissacarídea 23-valente

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions

Contact Info

Product

Resources

About